Xytex Implements Hereditary Cancer Genetic Testing in Donor Screening Protocols

Xytex Enhances Donor Screening with Genetic Testing

In a significant development for reproductive medicine, Xytex Corporation has announced an upgrade to its donor screening procedures by integrating hereditary cancer genetic testing into its protocol. This evolution is a reflection of Xytex’s commitment to adapting its practices to the latest advancements in genetic science and medicine. As of January 2026, this new protocol has been in place for all new donor candidates, aiming to increase the quality and safety of donor selections. The first screened donors under this protocol are expected to soon become available on the Xytex donor website.

Xytex, a pioneer in donor sperm services established in 1975, has a long history that includes innovations such as sperm cryopreservation and expanding genetic screening methodologies. The company began pilot testing Natera’s Empower hereditary cancer test in late 2025, recognizing the potential for genetic testing to furnish additional valuable information. Mary Anna Hamilton, President of Xytex, emphasized the importance of understanding genetic factors in donor selection: “As genetic science advances, we have to keep evaluating what information can meaningfully inform donor selection.”

The Empower test focuses on identifying inherited variants that may indicate a predisposition to cancer, differing from traditional carrier screenings that assess genetic variants associated with conditions that might affect a child. Dr. Todd Spradlin, Chief Medical Officer at Xytex, noted that the introduction of hereditary cancer testing adds an essential layer of information for intended parents and their healthcare teams, allowing for more informed choices during donor selection.

The Importance of Hereditary Cancer Testing

Hereditary cancer testing expands what genetic information is considered in donor screening processes. By evaluating specific inherited variants associated with cancer risks, Xytex provides a more holistic view of a donor’s genetic profile. This vital information contributes to the safety and health of future children conceived using donor sperm, leading to better outcomes for families.

Xytex has adopted Natera's Empower hereditary cancer test as an integral part of this redesigned screening process. Unlike the reproductive carrier screening performed by Natera’s Horizon test, which has been the standard part of donor evaluations, the Empower test represents a significant addition. This is crucial as it not only reassures intended parents about the donor's health history but also fortifies the overall integrity of the donor selection framework.

Preparing Families and Clinics for New Screening Procedures

As the first donors screened under this extensive protocol become accessible, their hereditary cancer testing information will be integrated into their donor profiles. This ensures that intended parents can make well-rounded decisions based on comprehensive genetic and health data. However, it is noteworthy that some donors who were accepted prior to the inclusion of these tests will still be uploaded to the website without hereditary cancer testing data, as their qualification processes were completed using Xytex’s original screening protocols.

This addition to donor screening exemplifies Xytex’s dedication to providing a safe and advanced reproductive service, enhancing not only the health of the donors but also those of their future offspring. As genetic science evolves, institutions like Xytex must continue to refine and expand their screening practices for the benefit of families seeking assisted reproductive services.

For families considering the use of donor sperm, this development signals a heightened level of scrutiny and care. Xytex, committed to continuously enhancing its donor screening processes, helps families navigate the complex journey of building their families while prioritizing health and safety.

For further details regarding Xytex's expanded donor screening initiative and the integration of hereditary cancer testing, interested parties may visit the Xytex Empower information page.

About Xytex

Xytex has been dedicated to helping families grow for over five decades, providing not only donor sperm but also extensive donor screening information and personalized client support. As reproductive medicine continues to evolve, Xytex promises to adapt its services to meet the changing needs of families globally. For more information, visit their official website at Xytex.com.